Unifying CRM and EWOC designs for phase I cancer clinical trials
DOI10.1016/J.JSPI.2008.07.005zbMATH Open1284.62651OpenAlexW2091515145MaRDI QIDQ1007501FDOQ1007501
Authors: Pei-Ling Chu, Yong Lin, Weichung Joe Shih 
Publication date: 20 March 2009
Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jspi.2008.07.005
Recommendations
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
- Continual reassessment and related dose-finding designs
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
continual reassessment methodmaximum tolerated dosedose-limiting toxicityescalation with overdose controlphase I cancer clinical trial
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Miscellanea. On sequential designs in nonlinear problems
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Non-parametric optimal design in dose finding studies
- Continual reassessment designs with early termination
- Prediction Approaches to Sequentially Searching for an Optimal Dose
Cited In (8)
- A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
- PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
- Adaptive clinical trial designs for phase I cancer studies
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
Uses Software
This page was built for publication: Unifying CRM and EWOC designs for phase I cancer clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1007501)
